Company Encyclopedia
View More
name
Nipro Corporation
8086.JP
News
View More

Goodman Co. to Become Nipro Vascular Corporation in 2026

Nipro Subsidiary Goodman Co., Ltd. to Be Renamed Nipro Vascular Corporation in 2026 Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nipro Corporation published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

Reuters·
8086
0.00%
Reuters·
8086
0.00%

Nipro Corporation Forms Consortium to Develop New Mpox Detection Kit

Nipro Corporation has formed a consortium with the GHIT Fund, TBA Co. Ltd., JIHS, PATH, and INRB to develop a new Mpox detection kit. This collaboration aims to leverage Nipro's genetic testing and TBA's Iso-PAS technology, with prototype evaluations in the Democratic Republic of the Congo. The initiative seeks to enhance early treatment and prevent infection spread, particularly in regions with limited medical infrastructure.

Reuters·
8086
0.00%
Reuters·
8086
0.00%

Should Nipro's (TSE:8086) Lower Dividend Prompt a Rethink of Its Capital Allocation Strategy?

Nipro Corporation announced a second-quarter dividend reduction from ¥12.00 to ¥10.00 per share for the fiscal year ending March 31, 2026. This change signals a shift in capital allocation strategy, possibly due to changing cash flow expectations. Despite the dividend cut, Nipro's core business prospects remain unchanged, though investors should watch for further changes in payout policy. The stock is currently trading above its fair value, with fair value estimates clustering at ¥1,448 per share.

Simplywall·
8086
0.00%
Simplywall·
8086
0.00%

Nipro Affiliate Spryte Medical Wins FDA IDE Approval for Brain Aneurysm Imaging Trial

Spryte Medical, a Nipro affiliate, has received FDA IDE approval to start the INSYTE US pivotal trial, evaluating its nOCT Imaging System for brain aneurysm treatment. Nipro holds a minority stake in Spryte Medical. This marks a significant milestone for the company in advancing medical imaging technology.

Reuters·
8086
0.00%
Reuters·
8086
0.00%

Nipro to Acquire Full Ownership of G2/Spryte Holdco

Nipro Corporation's Board of Directors has decided to acquire full ownership of G2/Spryte Holdco, LLC, currently holding 39% of the company. The acquisition aims to enhance Nipro's strategic position and support long-term growth, with the transaction set to begin on December 19, 2025. The financial implications are still under review, with further disclosures expected if necessary.

Reuters·
8086
0.00%
Reuters·
8086
0.00%
© 2025 Longbridge｜Disclaimer